Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
Tue, 17.09.2024
Helvetia Holding AG
Helvetia Holding AG
/ Key word(s): Bond
Helvetia redeems hybrid bond
17.09.2024 / 07:00 CET/CEST
Media release
St.Gallen, 17 September 2024
Helvetia has decided to redeem a CHF 225 million hybrid bond on its first optional redemption date on 17 October 2024.
Helvetia has decided to exercise its option to redeem the C [ … ]
Tue, 17.09.2024
Helvetia Holding AG
Helvetia Holding AG
/ Key word(s): Bond
Helvetia redeems hybrid bond
17.09.2024 / 07:00 CET/CEST
Media release
St.Gallen, 17 September 2024
Helvetia has decided to redeem a CHF 225 million hybrid bond on its first optional redemption date on 17 October 2024.
Helvetia has decided to exercise its option to redeem the C [ … ]
Tue, 17.09.2024
Helvetia Holding AG
Helvetia Holding AG
/ Key word(s): Bond
Helvetia redeems hybrid bond
17.09.2024 / 07:00 CET/CEST
Media release
St.Gallen, 17 September 2024
Helvetia has decided to redeem a CHF 225 million hybrid bond on its first optional redemption date on 17 October 2024.
Helvetia has decided to exercise its option to redeem the C [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Tue, 17.09.2024
Formycon AG
Press Release // September 17, 2024
Formycon will present clinical data on its ustekinumab biosimilar candidate FYB202 at the EADV Congress in Amsterdam and the UEG Week in Vienna
Planegg-Martinsried – Formycon AG (FWB: FYB) will present clinical study data of its ustekinumab biosimilar candidate FYB202 at this year's European Academy of Derma [ … ]
Mon, 16.09.2024
Mynaric AG
Shipments will support the Space Development Agency’s Tranche 1 programMUNICH, September 16, 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced the successful advancement of the company’s volume production ramp for the CONDOR Mk3. Mynaric conti [ … ]
Mon, 16.09.2024
Mynaric AG
Shipments will support the Space Development Agency’s Tranche 1 programMUNICH, September 16, 2024 – Mynaric (NASDAQ: MYNA) (FRA: M0YN), a leading provider of industrialized, cost-effective and scalable laser communications products, today announced the successful advancement of the company’s volume production ramp for the CONDOR Mk3. Mynaric conti [ … ]
Mon, 16.09.2024
HBM Healthcare Investments AG
HBM Healthcare Investments AG
/ Key word(s): Monthly Figures
Key Figures
15.9.2024
16.09.2024 / 17:47 CET/CEST
in CHF
Performance in %
15.09.2024
MTD
FYTD
CYTD
NAV*
229.03
-1.0
-4.7
[ … ]
Mon, 16.09.2024
HBM Healthcare Investments AG
HBM Healthcare Investments AG
/ Key word(s): Monthly Figures
Key Figures
15.9.2024
16.09.2024 / 17:47 CET/CEST
in CHF
Performance in %
15.09.2024
MTD
FYTD
CYTD
NAV*
229.03
-1.0
-4.7
[ … ]
Mon, 16.09.2024
FUCHS SE
FUCHS and E-Lyte open the first German production plant for electrolyte solutions in Kaiserslautern
On September 13, 2024, the first German production plant for electrolyte solutions was officially opened at the FUCHS site in Kaiserslautern. With a production volume of up to 20,000 tons of electrolyte per year, E-Lyte Innovations GmbH is setting a [ … ]